Products
Avelumab Biosimilar Monoclonal Antibody (PD-L1) for Research
Pre-Made Avelumab biosimilar, Whole mAb, Anti-CD274/PD-L1 Antibody: Anti-B7-H/B7H1/PDCD1L1/PDCD1LG1 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Avelumab, sold under the brand name Bavencio, is a fully human monoclonal antibody medication for the treatment of Merkel cell carcinoma, urothelial carcinoma, and renal cell carcinoma.
Order Information
| Catalog No. | Package | List Price(In USD) | Discount off | Discount Price |
|---|---|---|---|---|
| GMP-Bios-ab-040-1mg | 1mg | 3090 |
Size： 1mg | 10mg | 100mg
Product Details
| Products Name (INN Index) | Pre-Made Avelumab biosimilar, Whole mAb, Anti-CD274/PD-L1 Antibody: Anti-B7-H/B7H1/PDCD1L1/PDCD1LG1 therapeutic antibody |
| INN Name | Avelumab |
| Target | PD-L1 |
| Format | Whole mAb |
| Derivation | Human |
| Species Reactivity | Human |
| CH1 Isotype | IgG1 |
| VD LC | Lambda |
| Highest_Clin_Trial (Jan '20) | Approved |
| Est. Status | Active |
| 100% SI Structure | 4nki:HL/5grj:HL |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2015 |
| Year Recommended | 2016 |
| Companies | AIO Studien gGmbH;Array BioPharma;Chong Kun Dang;Dana-Farber Cancer Institute;Debiopharm;eFFECTOR Therapeutics;EMD Serono;Forty Seven;Fred Hutchinson Cancer Research Center;Gachon University Gil Medical Center;Hellenic Cooperative Oncology Group;Hospices Civils de Lyon;Johannes Gutenberg-University Mainz;M. D. Anderson Cancer Center;Merck KGaA;National Cancer Institute (USA);National Cancer Institute Slovakia;Netherlands Cancer Institute;Pfizer;Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins;Syndax Pharmaceuticals;Transgene;University College London;University of Birmingham;University of California San Diego;University of Iowa;Vaccinex;Vanderbilt-Ingram Cancer Center;VAXIMM;Verastem Oncology;Washington University School of Medicine |
| Conditions Approved | Merkel cell carcinoma;Urogenital cancer;Renal cell carcinoma |
| Conditions Active | Breast cancer;Diffuse large B cell lymphoma;Gastric cancer;Head and neck cancer;Non-small cell lung cancer;Ovarian cancer;Bladder cancer;Endometrial cancer;Fallopian tube cancer;Germ cell and embryonal neoplasms;Gestational trophoblastic disease;Glioblastoma;Haemangiosarcoma;Intestinal cancer;Leiomyosarcoma;Nasopharyngeal cancer;Neuroendocrine tumours;Osteosarcoma;Peripheral T-cell lymphoma;Peritoneal cancer;Prostate cancer;Recurrent respiratory papillomatosis;Small cell lung cancer;Solid tumours;Squamous cell cancer;Thymoma;Liposarcoma;Lymphoma;Oropharyngeal cancer;Pancreatic cancer;Acute myeloid leukaemia;Follicular lymphoma;Hodgkin's disease;Liver cancer;Meningioma;Bone metastases;Anal cancer;Cervical cancer;Vulvovaginal cancer;Meningioma |
| Conditions Discontinued | na |
| Development Tech | Human Phage Display |
About target - CD274
1. Protein Programmed cell death 1 ligand 1
2. Gene CD274
3. Organism Homo sapiens (Human)
Function
Plays a critical role in induction and maintenance of immune tolerance to self (PubMed:11015443, PubMed:28813417, PubMed:28813410).
As a ligand for the inhibitory receptor PDCD1/PD-1, modulates the activation threshold of T-cells and limits T-cell effector response (PubMed:11015443, PubMed:28813417, PubMed:28813410).
Through a yet unknown activating receptor, may costimulate T-cell subsets that predominantly produce interleukin-10 (IL10) (PubMed:10581077).
The PDCD1-mediated inhibitory pathway is exploited by tumors to attenuate anti-tumor immunity and escape destruction by the immune system, thereby facilitating tumor survival (PubMed:28813417, PubMed:28813410).
The interaction with PDCD1/PD-1 inhibits cytotoxic T lymphocytes (CTLs) effector function (By similarity).
The blockage of the PDCD1-mediated pathway results in the reversal of the exhausted T-cell phenotype and the normalization of the anti-tumor response, providing a rationale for cancer immunotherapy (By similarity).
